Xanthatin synergizes with cisplatin to suppress homologous recombination through JAK2/STAT4/BARD1 axis in human NSCLC cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Xanthatin synergizes with cisplatin to suppress homologous recombination through JAK2/STAT4/BARD1 axis in human NSCLC cells

Published:2021-01-13 Issue:3 Volume:25 Page:1688-1699
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J Cell Mol Med

Author:

Zhang Jian¹^ORCID,Yang Sheng²³⁴,Guan Hongmei²,Zhou Jueyu²^ORCID,Gao Yuan²

Affiliation:

1. Department of Medical Genetics School of Basic Medical Sciences Southern Medical University Guangzhou China

2. Department of Biochemistry and Molecular Biology School of Basic Medical Sciences Southern Medical University Guangzhou China

3. The First School of Clinical Medicine Southern Medical University Guangzhou China

4. Nanfang Hospital Southern Medical University Guangzhou China

Funder

Natural Science Foundation of Guangdong Province

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.16271

Reference50 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

4. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

5. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developmental toxicity assay of xanthatin in zebrafish embryos;Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology;2024-09

2. Phytochemical and pharmacological properties of Xanthium species: a review;Phytochemistry Reviews;2024-05-09

3. Identification and validation of LINC01322 as a potential prognostic biomarker and oncogene promoting tumor progression in lung adenocarcinoma;The International Journal of Biochemistry & Cell Biology;2024-04

4. Lung cancer treatment potential and limits associated with the STAT family of transcription factors;Cellular Signalling;2023-09

5. Xanthatin induce DDP‐resistance lung cancer cells apoptosis through regulation of GLUT1 mediated ROS accumulation;Drug Development Research;2023-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3